Journal of Virology, March 2009, p. 2789-2794, Vol. 83, No. 6
0022-538X/09/$08.00+0 doi:10.1128/JVI.02191-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Center for Vaccine Development,1 Departments of Pediatrics,2 Medicine, University of Maryland School of Medicine, 685 West Baltimore St., Room 480, Baltimore, Maryland 21201,3 Novartis Vaccines and Diagnostics, 4650 Horton Street, Emeryville, California 946084
Received 16 October 2008/ Accepted 28 December 2008
Measles remains an important cause of pediatric morbidity and mortality in developing countries, especially among infants who are too young to receive the current licensed live attenuated measles vaccine. We developed two Sindbis virus DNA vaccines encoding the measles virus hemagglutinin (pMSIN-H) and fusion proteins (pMSINH-FdU) and examined their immunogenicities and protective efficacies when administered alone or followed by the live measles virus vaccine in cotton rats. Neutralizing antibodies, mucosal and systemic antibody-secreting cells, memory B cells, and gamma interferon-secreting T cells developed after priming and increased after boosting. pMSIN-H priming conferred 100% protection against pulmonary measles, whereas pMSINH-FdU protected only in conjunction with the live measles virus vaccine boost.
Published ahead of print on 7 January 2009.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»